deltatrials
Terminated PHASE1 INTERVENTIONAL 3-arm NCT02974725

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma

Sponsor: Novartis Pharmaceuticals

Conditions Melanoma Non-Small Cell Lung Cancer
Interventions LTT462 LXH254 Ribociclib Trametinib
Updated 40 times since 2017 Last updated: Apr 9, 2025 Started: Feb 24, 2017 Primary completion: Apr 24, 2024 Completion: Apr 24, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business reasons

Other terminated trials from Novartis Pharmaceuticals

See all terminations from Novartis Pharmaceuticals

Other Melanoma trials with similar outcome

Browse all Melanoma trials

This PHASE1 trial investigates Melanoma and Non-Small Cell Lung Cancer and is currently terminated or withdrawn. Novartis Pharmaceuticals leads this study, which shows 40 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Oct 2017 · 5 months · monthly snapshot~Oct 2017 – ~May 2018 · 7 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Jul 2019 · 5 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Nov 2023 · 4 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~May 2024 · 5 months · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Sep 2025 · 4 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

40 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. May 2025 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Sep 2024 — May 2025 [monthly]

    Terminated PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  5. Jun 2024 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

▶ Show 35 earlier versions

  1. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Dec 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE1

  5. May 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE1

  6. Mar 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE1

  7. Sep 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1

  8. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  9. Feb 2022 — May 2022 [monthly]

    Recruiting PHASE1

  10. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE1

  11. Nov 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  12. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE1

  13. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  14. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  15. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE1

  16. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  17. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  18. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE1

  19. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  20. Jul 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  21. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE1

  22. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE1

  23. Feb 2020 — May 2020 [monthly]

    Recruiting PHASE1

  24. Nov 2019 — Feb 2020 [monthly]

    Recruiting PHASE1

  25. Aug 2019 — Nov 2019 [monthly]

    Recruiting PHASE1

  26. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  27. Feb 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  28. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  29. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  30. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  31. Oct 2017 — May 2018 [monthly]

    Recruiting PHASE1

  32. May 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  33. Mar 2017 — May 2017 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  34. Feb 2017 — Mar 2017 [monthly]

    Not Yet Recruiting PHASE1

  35. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Boston, United States , Cologne, Germany , Dresden, Germany , Essen, Germany , Frankfurt, Germany , Houston, United States , Leuven, Belgium , Lyon, France , Madrid, Spain and 19 more locations